Menü
You have to log in or sign up before you can proceed.
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

UnitedHealth Wants to Be the Next Tech Incubator
UnitedHealth Wants to Be the Next Tech Incubator
It appears UnitedHealth Group (NYSE: UNH), the largest health insurer in the U.S., doesn't think the market is moving fast enough to develop new healthcare technology. On Tuesday, the company....
Healthcare Investing Risks and How to Mitigate Them
Healthcare Investing Risks and How to Mitigate Them
Healthcare is constantly coming under the fire of political and media attention, and biotech companies are going boom or bust on FDA approvals that are out of their control. But healthcare is also....
What You Need to Know About Systematic Risk
What You Need to Know About Systematic Risk
We're a stock-picking company at The Motley Fool, and we tend to sing the praises of investing in individual companies for the long term -- but that's not to say that stock-picking is without its....
Here's How Alnylam Pharmaceuticals, Inc. Crushed It in 2017
Here's How Alnylam Pharmaceuticals, Inc. Crushed It in 2017
After a horrible 2016 following the loss of its lead drug candidate, Alnylam Pharmaceuticals (NASDAQ: ALNY) has had a pretty stellar year, up 238% so far.Much of that increase has come in the last....
Why Ekso Bionics Dropped as Much as 15.8% Wednesday
Why Ekso Bionics Dropped as Much as 15.8% Wednesday
Shares of exoskeleton suit leader Ekso Bionics (NASDAQ: EKSO) fell nearly 16% Wednesday without any new sales reports. The company did issue a new press release, but it detailed the results of....
Here's Where Things Went Wrong for Celldex Therapeutics, Inc. in 2017
Here's Where Things Went Wrong for Celldex Therapeutics, Inc. in 2017
For Celldex Therapeutics (NASDAQ: CLDX), 2016 was a horrible year. The biotech stock dropped 77% after experimental vaccine Rintega flopped in a late-stage clinical study. Celldex entered 2017....
Why 2017 Was a Year to Remember for Illumina, Inc.
Why 2017 Was a Year to Remember for Illumina, Inc.
Happy days are here again for Illumina, Inc. (NASDAQ: ILMN).Shareholders were accustomed to huge gains for the stock in previous years, but they were sorely disappointed by the gene-sequencing....
3 Top Big Pharma Stocks to Buy Now
3 Top Big Pharma Stocks to Buy Now
Big pharma stocks have been longtime favorites among investors for several reasons. The fact that they're big means that that they generate huge cash flow, which typically translates to attractive....
3 Dividend Stocks With Better Yields Than McDonald's
3 Dividend Stocks With Better Yields Than McDonald's
If you want fast food, McDonald's Corporation (NYSE: MCD) might be a good option. But despite the stock's status as a Dividend Aristocrat, there are better alternatives than McDonald's if you're....
3 Growth Stocks for the Long Term
3 Growth Stocks for the Long Term
What investor doesn't like growth? If a stock generates enough growth, dividends and valuation become relatively insignificant. Growth is king.We asked three Motley Fool investors which growth....
Is First Data Corp. a Buy?
Is First Data Corp. a Buy?
First Data Corp. (NYSE: FDC) is a payment-processing company that offers retailers card and mobile payment acceptance capabilities for online and point-of-sale (POS) transactions. First Data is....
Why Aratana Therapeutics Inc. Is Tanking Today
Why Aratana Therapeutics Inc. Is Tanking Today
In response to announcing a secondary common stock offering, shares of Aratana Therapeutics (NASDAQ: PETX), a commercial stage biotech focused on pet health, fell 14% as of 11:35 a.m. EST on....

	 
Medicrea acquiert 3 brevets auprès du Dr Paul McAfee et développe la planification chirurgicale des dispositifs intersomatiques titane imprimés en 3D
Medicrea acquiert 3 brevets auprès du Dr Paul McAfee et développe la planification chirurgicale des dispositifs intersomatiques titane imprimés en 3D
Medicrea acquiert 3 brevets auprès du Dr Paul McAfee et développe la planification chirurgicale des dispositifs intersomatiques titane imprimés en 3D Lyon et New York, 28 novembre, 2017 - Le....
Evotec: Schnäppchen oder fallendes Messer?
Evotec: Schnäppchen oder fallendes Messer?
Evotec ist in diesen Tagen wieder in aller Munde. Der Aktienkurs kommt nicht auf die Beine und nach dem Ausverkauf der letzten Wochen um zeitweise bis zu 46 Prozent auf 12 EUR, wittern viele....
Why Omeros Corporation Is the Best Buy in Biotech Right Now
Why Omeros Corporation Is the Best Buy in Biotech Right Now
Omeros Corporation (NASDAQ: OMER) stock soared after the company reported surprisingly good results recently, but there's a lot more fuel in the tank to propel it even higher. This small-cap....
This Small-Cap Biotech Stock Is Onto Something Big
This Small-Cap Biotech Stock Is Onto Something Big
I recently had the pleasure of chatting with Flexion Therapeutics (NASDAQ: FLXN) CEO Mike Clayman about the company's plans for Zilretta, a newly approved medicine treating osteoarthritis of the....
Why Quidel Corporation Is Sinking
Why Quidel Corporation Is Sinking
After the company announced that it is being sued by one of its customers, shares of Quidel Corporation (NASDAQ: QDEL), a maker of diagnostic testing equipment, fell 10% as of 3:45 p.m. EST on....
Biogen Inc. Buys Its Way Out of Competition
Biogen Inc. Buys Its Way Out of Competition
Biogen (NASDAQ: BIIB) is following the old saying, "If you can't beat 'em, join 'em" for its multibillion drug Tecfidera or, more accurately, "If you might not be able to beat 'em later, license....
Better Buy: Eli Lilly and Co. vs. Merck & Co., Inc.
Better Buy: Eli Lilly and Co. vs. Merck & Co., Inc.
These big pharma stocks have something for everyone. Income investors love the dividends Eli Lilly and Co. (NYSE: LLY) and Merck & Co., Inc. (NYSE: MRK) pay each quarter, while dreams of....
What Will the Average American Pay for Obamacare in 2018?
What Will the Average American Pay for Obamacare in 2018?
Big changes are in store for consumers who are planning to purchase an Obamacare (officially the Affordable Care Act, or ACA) plan in 2018. Though the enrollment period is ongoing and remains the....
3 Top Diabetes Stocks to Buy Now
3 Top Diabetes Stocks to Buy Now
Diabetes is huge problem for Americans. Between 1990 and 2010, the number of U.S. residents with diabetes tripled, and the number of new cases annually doubled. Both prevalence and costs....
Can Teladoc Stock Keep Going After Last Week's 24% Pop?
Can Teladoc Stock Keep Going After Last Week's 24% Pop?
One of last week's biggest winners makes house calls. Teladoc (NYSE: TDOC) soared 24.1% last week, making it the second best performer on the New York Stock Exchange. Teladoc moved higher after....
The Federal Government Just Broke Its Medical-Marijuana Promise
The Federal Government Just Broke Its Medical-Marijuana Promise
Few if any industries are growing at a quicker and more consistent pace in the U.S. than marijuana. A report released earlier this year by Marijuana Business Daily entitled "Marijuana Business....
5 Cancer Types With the Poorest Long-Term Outlook
5 Cancer Types With the Poorest Long-Term Outlook
There's arguably no scarier diagnosis a patient can receive from their doctor than cancer. But the grim reality, based on data from the National Cancer Institute's Surveillance, Epidemiology, and....
How to Diversify Your Healthcare Investments
How to Diversify Your Healthcare Investments
On this week's episode of Industry Focus: Healthcare, analysts Kristine Harjes and Todd Campbell get back to basics and explain what you need to know about diversifying your portfolio, especially....